RESUMEN
To determine the efficacy and safety of subconjuctival injection of mitomycin C versus daunorubicin for treatment of pterygium. This randomized double blind placebo-controlled clinical trial included 54 eyes of 36 patients with pterygium who were referred to Al-Zahra Hospital, Zahedan-Iran in 2004. Eyes were randomly assigned to three groups including mitomycin C, daunorubicin or placebo. The injection was performed subconjuctivally at limbus under the pterygium. Patients were examined before and one month after injection. Change in symptoms and size reduction of pterygia and complications were compared among the three groups. There was no statistically significant difference between the three groups in terms of age and primary pterygium size. Post-injection reduction in symptoms and pterygium size had no significant difference among the three groups. Post-njection complication rates were 72.2%, 93.3% and 40% in the mitomycin, daunorubicin and placebo groups, respectively. Serious complications were not seen in any group. Subconjuctival injection of mitomycin C and daunorubicin for treatment of pterygium is relatively safe, but has little effect in reducing symptoms and pterygium size
RESUMEN
To determine the safety and efficacy of mitomycin-C injection into the lacrimal duct for treatment of partial nasolacrimal duct obstruction in adults. This is a before-after clinical trial performed on 20 patients with partial primary acquired nasolacrimal duct obstruction. We injected 1.5 ml of mitomycin-C 0.2 mg/ml into the lacrimal duct and repeated it with concentration of 0.3 mg/ml for inadequate response. After 9 months of follow up, epiphora decreased in 80% of the patients, while the amount of obstruction decreased to 50%. In patients with low grade anatomical obstruction the improvement was 100% and with increasing degrees of obstruction, the success rate of this intervention decreased. Ophthalmic complications did not occur and nasal mucosal pallor was observed only in one patient. Intraductal mitomycin injection can reduce epiphora in adults with partial primary acquired nasolacrimal duct obstruction and is a safe method
RESUMEN
To evaluate the range of accommodation lag and it's signs and symptoms in 20-25 year-old female students at Zahedan Medical School, Iran. Three-hundred female students were enrolled for assessment of accommodation. After exclusion of individuals with individuals with accommodation disorders in 3 steps including amplitude of accommodation, accommodative facility, and relative accommodation; 216 students remained and were assessed for accommodative response and lag. Of 216 eligible persons, 28 [13%] had no accommodation lag. Accommodation lag of other degrees were as follow: +0.25 in 42 [19.4%], +0.50 in 40 [18.5%], +0.75 in 39 [18.1%], +1.00 in 51 [23.6%], +1.25 in 4 [1.9%], +1.5 in 10 [4.6%], and +1.75 in 2 [0.9%]. None of the 149 participations with accommodation lag of 0.00 to + 0.75 had any problem. From 51 persons with +1 accommodation lag, 6 [11.8% or 2.8% of total] had eye strain and 4 [2.8% or 1.9% of total] had both burning and eye strain. Overall, 4.2% had burning eye strain. Accommodation lag assessment is a necessary exam for complaints of eye strain and burning